Ad
related to: maalox deficiency treatment information
Search results
Results From The WOW.Com Content Network
The antacid, Maalox Maalox was a brand of antacid owned by Sanofi.Their main product is a flavored liquid containing a suspension of aluminum hydroxide and magnesium hydroxide, which act to neutralize or reduce stomach acid, for the purpose of relieving the symptoms of indigestion, heartburn, gastroesophageal reflux disease, and also stomach or duodenal ulcers.
Treatment for all forms of this condition primarily relies on a low-protein diet, and depending on what variant of the disorder the individual suffers from, various dietary supplements. All variants respond to the levo isomer of carnitine as the improper breakdown of the affected substances results in sufferers developing a carnitine deficiency.
Although methylmalonic acidemia has a variety of causes, both genetic and dietary, methylmalonyl CoA mutase deficiency is an autosomal recessive genetic disorder. Patients with the deficiency either have a complete gene lesion, designated as mut0 or a partial mutation in the form of a frameshift designated as mut-.
Maalox was developed in collaboration between William H. Rorer, Inc. and a medical doctor and researcher specializing in gastrointestinal issues, Alison Howe Price from Philadelphia. [3] The collaboration came about after World War II when Claude Newhart, a salesman and pharmacist for the company had an idea that he thought might change the ...
Malonic aciduria or malonyl-CoA decarboxylase deficiency (MCD) is an autosomal-recessive [1] metabolic disorder caused by a genetic mutation that disrupts the activity of Malonyl-CoA decarboxylase. This enzyme breaks down Malonyl-CoA (a fatty acid precursor and a fatty acid oxidation blocker) into acetyl-CoA and carbon dioxide .
Most of the organic acidemias result from defective autosomal genes for various enzymes important to amino acid metabolism.Neurological and physiological harm is caused by this impaired ability to synthesize a key enzyme required to break down a specific amino acid, or group of amino acids, resulting in acidemia and toxicity to specific organs systems.
Olipudase alfa was approved for medical use in Japan in March 2022. [6]In May 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Xenpozyme, intended for the treatment of non-central nervous system (CNS) manifestations of acid ...
NGLY1 deficiency is a very rare genetic disorder caused by biallelic pathogenic variants in NGLY1. It is an autosomal recessive disorder. Errors in deglycosylation are responsible for the symptoms of this condition. [ 1 ]